INTRODUCTION {#SEC1}
============

Female placental mammals transcriptionally silence one of the two X chromosomes to ensure a roughly equal gene dosage between males and females. This chromosome-wide silencing process, or X chromosome inactivation (XCI), is initiated early in development. Mouse XCI happens in two phases: imprinted and random XCI. Around the two- to four-cell stage, the paternal X chromosome is exclusively inactivated ([@B1]). This imprinted XCI is reverted in the inner cell mass of blastula ([@B2]). After implantation, either the paternal or maternal X chromosome is stochastically chosen to be inactivated in epiblast ([@B3]). Random XCI persists throughout the life.

Random XCI is believed to be triggered by upregulation of female-specific X-inactive-specific transcript (*Xist*) RNA from the future inactive X (Xi) chromosome ([@B4]). Overwhelming evidence shows *Xist* RNA acts *in cis* to coat the Xi chromosome and recruit epigenetic silencing factors. In both humans and mice, X chromosome does not initiate XCI without *Xist* RNA expression. Therefore, the consensus view is that *Xist* induction is necessary to initiate random XCI during development.

Differentiation of female mouse embryonic stem (ES) cells is the most favored model system to investigate *Xist* induction ([@B8]). Undifferentiated female ES cells derived from the inner cell mass exhibit two active X chromosomes. Mimicking embryo development, ES cell differentiation up-regulates *Xist* RNA from the future Xi chromosome, and goes through several stages to fully establish XCI ([@B4],[@B5],[@B9]). The initiation stage involves counting and selection of the future silenced X chromosome and induction of *Xist* RNA. With the embryoid bodies method, 48 h after induction of differentiation, *Xist* RNA spreads throughout and coats the Xi chromosome *in cis* ([@B10]). Then, high-order chromatin packaging and silencing of X-linked genes begin. Much later during differentiation (e.g. day 12 of differentiation), chromatin is further modified as XCI becomes fully established and irreversible. Maintenance of XCI appears independent of *Xist* RNA ([@B11]). Multiple studies have described transcriptional controls of the initial *Xist* up-regulation ([@B4]). The contribution of post-transcriptional regulation is still not well characterized.

The role of intron or splicing for long noncoding RNA like *Xist* is a mystery. Messenger RNA splicing generally promotes nuclear export and provides a mechanism to allow one protein-coding gene to generate multiple functional variants ([@B14],[@B15]), but neither applies to nuclear-retained *Xist* RNA. By UCSC annotation, *Xist* precursor RNA contains eight exons. Retaining and deleting the last intron generates a long and short *Xist* isoform, respectively. The long isoform is the major isoform, while the short isoform is expressed lowly and only in certain differentiated tissues ([@B16],[@B17]). Nevertheless, the two spliced variants were indistinguishable in mediating X-chromosome inactivation ([@B17]). Therefore, it is unclear why the *Xist* gene contains introns.

Notably, human and mouse *Xist* cDNA are only 47% identical but share a similar exon-intron structure, suggesting selection pressure to maintain *Xist* splicing ([@B18]). We asked whether *Xist* RNA splicing could be a regulatory checkpoint of *Xist* biogenesis. Surprisingly, we found that differentiation drastically increased *Xist* RNA splicing efficiency in C57BL/6 ES cells (or BL6 ES cells) and F1 2-1 ES cells (the hybrid of *Mus musculus 129SvJaeJ* and *Mus musculus castaneus* EiJ, which has been widely used to study allelic expression of *Xist* RNA and XCI). We and others previously discovered that RNA binding protein PTBP1 binds to *Xist* RNA ([@B19]). PTBP1 was also identified in a forward genetic screen as impairing *Xist*-dependent chromosome silencing ([@B22]). Since PTBP1 is well known to regulate splicing ([@B23]), we tested whether PTBP1 could be involved in differentiation-induced *Xist* splicing.

MATERIALS AND METHODS {#SEC2}
=====================

Cell culture {#SEC2-1}
------------

Feeder dependent female WT and *Ptbp1^−/−^* BL6 mouse ES cells were expanded on inactive male murine embryonic fibroblast (MEF) feeders on 0.1% gelatinized tissue culture plates in DMEM media (Gibco cat. no. 10313039) supplemented with 15% ESC grade FBS (Gibco cat. no. 10439024), 1% nucleosides (EMD Millipore cat. no. ES008D), 1% Glutamax (Gibco cat. no. 35050061), 0.1 mM β-mercaptoethanol (Acros Organics cat. no. 125472500), and 1000 U/ml mLIF (EMD Millipore cat. no. ESG1106). Feeder independent female WT and *Ptbp1^−/−^* BL6 mouse ES cells, and F1 2-1 mouse ES cells were expanded on 0.1% gelatinized tissue culture plates in 2i culture media containing 50% Neurobasal (Gibco cat. no. 21103049) and 50% DMEM/F12 (Gibco cat. no. 11320082) supplemented with 1% B27 + RA (Gibco cat. no. 17504044), 1% N2 Supplement (R&D System cat.no. AR009), 1% Glutamax, 7.4 mM B27 Fraction V (Gibco cat. no. 15260037), 1% Penicillin-Streptomycin (GE Healthcare Life Sciences cat. no. SV30010), 3 μM CHIR99021 (Sigma cat. no. SML1046), 1 μM PD0325901 (Selleckchem cat. no. S1036), 150 μM 1-thioglycerol (Sigma cat. no. M6145) and 1000 U/ml mLIF (Gemini Bio-Products cat. no. 400--495). To assist initial attachment, 2i medium was supplemented with 2% ESC grade FBS for the first 24 h before switching to serum free.

Differentiation of embryonic stem cells {#SEC2-2}
---------------------------------------

For monolayer differentiation, cells were plated feeder-free at 200--300 × 10^3^ per six-well and were grown in LIF conditions for 24 h and then LIF was removed and cells were grown in differentiation media for 24 h (DMEM supplemented with 15% ESC FBS, 1% nucleosides, 1% [l]{.smallcaps}-glutamine, 0.1 mM β-mercaptoethanol and 1 μM retinoic acid (Sigma cat. no. R2625)). To generate embryoid bodies, feeder independent ES cells were plated at a density of 2.5 × 10^6^ cells on 0.5% Agarose coated polystyrene dishes (Grenier Bio-One cat. no. 633102) and maintained in DMEM supplemented with 10% FBS, 1% Glutamax, 1% non-essential amino acids (GE Healthcare, cat. no. SH3023801), 1% sodium pyruvate (Lonza cat. no. 13-115E), and 0.1 mM betamercaptoethanol without mLIF. For western blots, WT and *Ptbp1--/--* mESCs were plated at 300 × 10^3^ on 0.5% agarose coated six-well dishes (VWR, cat. no. 10062-892) to generate embryoid bodies. To minimize cell death, media was replenished every 2 days.

Actinomycin D treatments {#SEC2-3}
------------------------

Cells were plated at 100 × 10^3^ per six-well for 24 h prior to actinomycin D treatment. For stability experiments, cells were treated with 5 μg/ml actinomycin-D (Sigma, cat. no. A1410) or an equal volume of DMSO vehicle (Sigma, cat. no. D2438) in growth media for 8 h. Percent *Xist* remaining was calculated as the ratio of *Xist* transcripts at the time of collection relative to time 0. For transcription inhibition prior to the inflection point of enhanced splicing, cells were differentiated for 6 h in media lacking LIF and supplemented with 1 μM retinoic acid. After 6 h of differentiation, cells were treated with 5 μg/ml actinomycin D for 4 h added directly to growth media. Total RNA was collected from undifferentiated cells (0 h), after 6 h of differentiation, and after 2 or 4 h of actinomycin D post treatment (8 and 10 h).

Generation of *Ptbp1^−/−^* ES cells {#SEC2-4}
-----------------------------------

Mouse *Ptbp1^loxp/loxp^* ES cells were generated following a previously published protocol ([@B27]). In brief, healthy E3.5 blastocysts were collected from *Ptbp1^loxp/loxp^* intercrosses and individually cultured in KSOM medium (DMEM high glucose with 15% (vol/vol) KO serum, 2 mM GlutaMAX,1 mM sodium pyruvate, 0.1 mM MEM NEAA, 0.1 mM β-mercaptoethanol, 103 U/ml of LIF, 1 μM PD0325901 and 3 μM CHIR99021. After overnight culture, blastocysts were transferred to defined serum-free medium (1:1 mixture of DMEM-F12/N2 and Neurobasal/B27, 1 mM GlutaMAX, 0.5 mM sodium pyruvate, 0.1 mM MEM NEAA, 0.1 mM β-Mercaptoethanol) plus 2i/LIF to allow attachment to the feeder layer. After outgrowth from blastocysts, cells were disaggregated and cultured in the serum-free medium plus 2i/LIF together with MEF. Cells were monitored daily for colony formation. Cells exhibiting differentiation or atypical ES cell morphology were discarded and the healthy ES cell lines were maintained in the serum-free medium plus 2i/LIF with MEF. *Ptbp1^−/−^* mES cells were generated via expressing Cre recombinase in *Ptbp1^loxp/loxp^* ES cells. Ptbp1 homozygous knockout ES cell clones were identified by PCR genotyping and confirmed by PTBP1 Western blot.

RNA Isolation, cDNA synthesis and RT-qPCR {#SEC2-5}
-----------------------------------------

Trizol isolation of RNA was performed following manufacturer\'s protocol (Life Technologies). Isolated RNA was treated with 4 units of Turbo DNase (Ambion) at 37°C for 35 min followed by Phenol-Chloroform extraction (pH 4.5, VWR cat. no. 97064-744). First-strand cDNA was generated using 1 μg RNA and 200 units of M-MLV reverse transcriptase (Promega cat. no. M1705) with a RT primer in a 20 μl reaction ([@B28]). For analyzing *Xist* expression and splicing, the strand-specific RT primer (50μM) was a *Xist* gene specific reverse primer (E6-E7 reverse) targeting exon 7 unless specified otherwise. For X-linked and differentiation genes, random hexamers (30 μM) were used. For polyadenylated (poly(A)+) RNA, oligodT primers (50μM) were used for cDNA generation. The RT-qPCRs were conducted using a Quantstudio 6 Flex Real-Time PCR instrument with 2x Syber Master Mix (Life Technologies) ([@B29],[@B30]). Three technical replicates of all samples were performed for each biological replicate. An additional no-template control was included in every experiment. Outliers were defined by a Ct variance higher than 0.5. Analysis was done with Quanstudio 6 software and Microsoft Excel. Statistics test were based on ΔCt (for *Xist* with the same RNA input) or ΔΔCt values (for other genes).

Splicing assay {#SEC2-6}
--------------

Splicing assays were performed essentially as previously described ([@B31]). Standard conditions for Taq polymerase from New England Biolabs (cat. no. M0267E) were used. For amplification of spliced regions of *Xist* spanning exons 1--2, exons 2--3 and exons 2--6, exon specific primers for corresponding exons were used ([Supplementary Table](#sup1){ref-type="supplementary-material"}). The PCRs were performed at 60°C (*T*~m~) for 29--35 cycles. PCR products \>1 kb were resolved in 1.5% TAE Agarose gel. Smaller products were resolved with capillary electrophoresis (QIAxcel Advanced System) or on a 2% TBE Agarose gel ([@B32]). Relative quantities of spliced and unspliced products were measured on the QIAxcel software (Qiagen) or ImageLab (Bio-Rad) and the splicing ratio was calculated as the molar ratio of spliced to unspliced PCR products. The electropherograms of capillary electrophoresis were converted to virtual gel images by QIAxcel for presentation.

Allele specific splicing assay and restriction fragment length polymorphism analysis {#SEC2-7}
------------------------------------------------------------------------------------

PCR reactions were performed under standard conditions for Taq polymerase (New England Biolabs) on RT products derived from F1 2-1 cells. For *Xist* 30--35 cycles was used. PCR products were digested with 2.5 units of Tfi1 (New England Biolabs cat. no. R0546L) for 2 h at 65°C. For single cell studies, PCR products were digested with 2.0 units of Tfi at 37°C overnight. For X-linked genes *G6pdx* and *Ogt*, 35--40 cycles were used. PCR products were digested with Ava1 (NEB, cat. no. R0152S) or ScrF1 (NEB, cat. no. R0110S) to cut *Ogt* or *G6pdx* respectively. Samples were purified using Agencourt AMPure XP magnetic beads (Beckman Coulter cat. no. A63881). Eluted PCR products were diluted 1:3--1:5 when necessary before analysis on the QIAxcel Capillary Electrophoresis system (Qiagen) using the QIAxcel DNA Screening Kit (Qiagen, cat. no. 929004). The QIAxcel Alignment Marker QX 15-600bp (Qiagen, cat. no. 929530) and the Qiaxcel 25--500 bp size marker (Qiagen, cat. no. 929560) were used in the analysis. For confirmation of allele specific digestion by Tfi1, genomic DNA collected from the brain of wildtype *Mus musculus castaneus* EIJ and *Mus musculus domesticus* 129S4/SvJaeJ mice were used.

Single cell sorting and cDNA preparation {#SEC2-8}
----------------------------------------

WT F1 2-1 ES cells were differentiated into embryoid bodies for 6--8 days. Cells were washed two times with 1× PBS and stained with propidium iodide (PI) (1:1500) (BD Pharmigen, cat. no. 556547). We used three stringent gating steps to select single cells: (i) negative staining of propidium iodide as an indicator of healthy cells; (ii) typical FSC and SSC settings to filter out cell debris and cell chunks; (iii) linearity between SSC height and SSC area to ensure single cell (singlet in sorting). Single PI-negative WT F1 2-1 cells from embryoid bodies were then sorted into PCR strips using a MoFlo Astrios EQ (Beckman Coulter) according to manufacturers\' protocol. The cDNA was prepared using SMART-Seq v4 Ultra Low Input Kit (Clontech) according to manufacturer\'s protocol.

Immunoblotting {#SEC2-9}
--------------

For primary antibodies, we used antibodies to PTBP1-NT (1:1000), PTBP1-CT (1:200), GAPDH (1:1000, Ambion, AM4300). For secondary antibodies, we used Alexa Fluor 488 donkey anti rabbit (Invitrogen, A21206) and AF 647 donkey anti mouse (Invitrogen, A31571).

RESULTS {#SEC3}
=======

ES cell differentiation induces *Xist* RNA splicing {#SEC3-1}
---------------------------------------------------

To systemically investigate the initial phase of *Xist* induction, we designed qPCR-quality primer pairs to measure total, spliced, and unspliced *Xist* transcripts. For total *Xist*, the primer pair targets the same exon and is indifferent to spliced vs. unspliced transcripts. For spliced *Xist*, the forward and reverse primers anneal to different exons separated by a large intron and are unable to amplify unspliced *Xist*. For unspliced *Xist*, each primer pair flanks a specific splice site hybridizing to the intron and exon respectively. We used multiple qualified primer pairs for each *Xist* species to increase the robustness of the analysis.

We performed strand-specific RT-qPCR and found total *Xist* was upregulated in F1 2-1 cells 24 h after differentiation in a monolayer culture (Figure [1A](#F1){ref-type="fig"}). We observed a much higher increase in the spliced *Xist* transcript, which in theory reflected the aggregated effect of splicing and RNA decay. By contrast, we found a modest but consistent decrease in the unspliced *Xist* transcript (Figure [1A](#F1){ref-type="fig"}), which should be caused by both transcription and splicing.

![Differentiation Induces *Xist* Splicing. (**A**) RT-qPCR analysis of total, spliced, and unspliced *Xist* transcripts. Adherent F1 2-1 cells were differentiated by LIF withdrawal and addition of RA. (**B**) Ratios of spliced/total *Xist* transcripts quantified by RT-qPCR. (**C**) Ratios of unspliced/total *Xist* transcripts quantified by RT-qPCR. (**D**) Splicing assay examines intron 2 splicing before and 24 h after differentiation. Representative virtual gel image of intron 2 splicing (*left* panel). Quantified intron 2 splicing ratio (*right* panel) (**E**) Splicing assay examines intron 1 splicing before and 24 h after differentiation. Representative virtual gel image of intron 1 splicing (*left* panel). Quantified intron 1 splicing ratio (*right* panel). (**F**) Splicing assay examines splicing from exon 2 to exon 6 before and 24 h after differentiation. Representative gel image (*left* panel). PCR cycles were 33 and 29 for undifferentiated and differentiated cells respectively. For differentiated cells, PCR amplification for 33 cycles did not produce the unspliced product and the spliced product was over saturated, so amplification of 29 cycles were used for the presentation. Quantified splicing ratio (*right* panel). Error bars indicate S.E.M. of three biological replicates. \**P*-value\<0.05; \*\**P*-value\<0.01; \*\*\**P*-value\<0.001 Student\'s *t*-test (one-tailed, unpaired).](gky1198fig1){#F1}

A reasonable explanation for these observations is that differentiation activates *Xist* transcription and splicing. To mask the transcription effect, we normalized the spliced and unspliced *Xist* to total *Xist*. After this normalization, the spliced/total *Xist* ratio was up-regulated by ∼2-fold (Figure [1B](#F1){ref-type="fig"}), whereas the unspliced/total *Xist* ratio down-regulated by ∼3-fold (Figure [1C](#F1){ref-type="fig"}).

Enhanced splicing is a parsimonious explanation for a decrease in the unspliced transcript and an increase in the spliced transcript. To directly test whether differentiation affects *Xist* RNA splicing, we designed a primer pair flanking intron 2 (the smallest intron of *Xist*) to simultaneously detect unspliced and spliced transcripts (Figure [1D](#F1){ref-type="fig"}). Intron 2 is 149 nt, so unspliced *Xist* can be reasonably detected alongside spliced *Xist* and allows calculation of a splicing ratio (spliced/unspliced) as a measure of splicing efficiency. We found differentiation clearly induced intron splicing (Figure [1D](#F1){ref-type="fig"}).

To test whether differentiation-induced splicing occurs for other introns, we focused on intron 1. We were unable to identify an effective primer pair flanking intron 1 to amplify the unspliced transcript, probably due to the size of intron 1 (2794 nt). Therefore, we designed an intronic forward primer upstream from the intron 1−exon 2 boundary and a reverse primer on exon 2 to detect the intron 1-containing unspliced variant. A multiplex RT-PCR reaction containing this primer pair and another forward primer on exon 1 effectively amplifies both the spliced (74 bp) and unspliced (127 bp) Xist transcripts. Consistently, we observed that splicing was significantly enhanced after differentiation (Figure [1E](#F1){ref-type="fig"}).

These data suggest a low splicing efficiency of *Xist* RNA in undifferentiated ES cells. An alternative possibility is higher stability of the spliced transcript in differentiated ES cells. To test this, we measured the half-lives of the spliced *Xist* transcript by measuring percentage of remaining transcripts upon actinomycin D treatment. We found no change in the stability of the spliced *Xist* transcript before or after differentiation ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

We next asked whether differentiation-induced *Xist* splicing was regulated *individually* per intron or *coordinated across* all introns. We reasoned that uncoordinated regulation of intron splicing would lead to isoforms whose introns were not 100% removed. In contrast, coordinated regulation would result in either fully unspliced or spliced transcripts (i.e. all-in or all-out). It was also possible that some, but not all, intron splicing was coordinated. To distinguish these possibilities, we used primers flanking multiple exons (2--6) to detect *Xist* transcripts.

Our results were consistent with the hypothesis that differentiation-induced *Xist* splicing is coordinated across introns: only completely spliced and unspliced transcripts were detected by RT-PCR (Figure [1F](#F1){ref-type="fig"}). Because PCR efficiency is skewed toward the spliced product and the unspliced product is much larger, spliced *Xist* was over-represented in this analysis. A recent study using long-read sequencing showed that most nascent RNAs are either fully spliced or fully unspliced in fission yeast ([@B33]). Our result suggests that this might also be happening in mammals.

Taken together, these data are consistent with the following model for *Xist* biogenesis: naïve ES cells express *Xist* transcripts, which remain largely unspliced due to splicing deficiency; differentiation enhances splicing efficiency while transcription ramps up. Enhancing splicing competence is thus likely one of the regulatory events of development-induced *Xist* expression.

Enhanced *Xist* splicing is independent of *Xist* transcription {#SEC3-2}
---------------------------------------------------------------

One outstanding question is whether pre-existing *Xist* becomes spliced upon differentiation or if only newly synthesized *Xist* is spliced. This can be tested by inhibiting *Xist* transcription before splicing activation and examining whether the pre-existing *Xist* transcripts become spliced. To do this, we first determined the timepoint of the splicing change. *Xist* splicing does not immediately increase upon differentiation with retinoic acid but begins to change around 7--8 h post differentiation (Figure [2A](#F2){ref-type="fig"}). After that *Xist* splicing is gradually enhanced until 18 h post differentiation. We therefore define 7 h post differentiation as the inflection point for splicing enhancement.

![Enhanced *Xist* splicing is independent of *Xist* transcription. (**A**) Representative RT-PCR virtual gel images of intron 1 splicing (*top* panel) and intron 2 splicing (*bottom* panel) in adherent F1 2-1 cells between 0--22 h post differentiation (RA induction and LIF withdrawal). (**B**) Schematic diagram of experimental procedures. Cells were differentiated for 6 hours before treatment with 5ug/ml Actinomycin D or control DMSO. RNA was collected before differentiation (time 0), for 6 h post differentiation induction (time 6), for 2 and 4 h post treatment (time 8 and time 10). Representative RT-PCR virtual gel image of (**C**) intron 1 and (**D**) intron 2splicing following the aforementioned experimental procedures. (**E--G**) RT-qPCR analysis of unspliced *Xist* transcripts using primers detecting various introns. (**H--J**) RT-qPCR of spliced *Xist* transcripts using primers for various exon--exon junctions. Error bars indicate S.E.M. of three biological replicates. ^\#^*P*-value = 0.06; \**P*-value \< 0.05; \*\*\**P*-value \< 0.001 Student\'s *t*-test (one-tailed, unpaired).](gky1198fig2){#F2}

We inhibited transcription with actinomycin D at 6 h post differentiation and analyzed *Xist* splicing at 8 and 10 h post differentiation (Figure [2B](#F2){ref-type="fig"}). In scenario 1, if only newly synthesized *Xist* is spliced, actinomycin D treatment will prevent the production of spliced *Xist*. In scenario 2, if pre-existing unspliced *Xist* RNA becomes spliced after the inflection point, spliced *Xist* transcripts will still be generated even with actinomycin D treatment. As a result, spliced *Xist* transcripts would appear abundant relative to unspliced *Xist* transcripts because unspliced *Xist* transcripts are lost to splicing without being supplied from transcription.

We found that the production of spliced *Xist* transcripts was largely unaffected by actinomycin D treatment (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). In contrast, unspliced *Xist* transcripts were clearly diminished by actinomycin D, consistent with transcription inhibition. This was observed with two different primer pairs examining splicing of two different introns. These data support scenario 2 showing that the pre-existing unspliced *Xist* RNA becomes spliced after the inflection point.

To quantitatively measure magnitudes of the expression changes in the spliced and unspliced *Xist* RNA individually, we performed RT-qPCR. Compared to before the inflection point (i.e. 6 h post differentiation), unspliced *Xist* stayed relatively flat after DMSO treatment but decreased by about 4-fold as early as 2 h after actinomycin D treatment (Figure [2E](#F2){ref-type="fig"}--[G](#F2){ref-type="fig"}). In contrast, spliced *Xist* remained up-regulated after actinomycin D treatment (Figure [2H](#F2){ref-type="fig"}--[J](#F2){ref-type="fig"}). Therefore, differentiation-induced splicing continues in actinomycin D-treated cells.

The above results indicate that *Xist* splicing can occur post-transcriptionally, because most pre-existing unspliced *Xist* transcripts likely have completed their transcription. Also supporting post-transcriptional splicing of *Xist* was that data concerning splicing of the upstream (e.g. intron 1) and downstream introns (e.g. introns 3, 4 and 5) were consistent with one another (Figure [2E](#F2){ref-type="fig"}--[J](#F2){ref-type="fig"}). *Xist* transcripts are polyadenylated ([@B34]). To further test whether *Xist* splicing is post-transcriptional, we analyzed *Xist* splicing in polyadenylated (poly(A)+) RNA fractions. We found most polyadenylated *Xist* transcripts were unspliced in ES cells and the splicing of these poly(A)+ *Xist* RNA was enhanced by differentiation ([Supplementary Figure S2A-B](#sup1){ref-type="supplementary-material"}).

Taken together, these data show that *Xist* splicing can occur post-transcriptionally. We could not rule out co-transcriptional *Xist* splicing. Co-transcriptional splicing could be tested with nascent chromatin-associated RNA fractions under the assumption that chromatin-associated RNAs undergo transcription and post-transcriptional RNAs are detached from chromatin. However, *Xist* RNA is tethered to the X chromosome, so an analysis of chromatin-associated RNA would not be informative.

Allelic difference in *Xist* RNA splicing efficiency is associated with nonrandom *Xist* induction {#SEC3-3}
--------------------------------------------------------------------------------------------------

Although largely random, differentiation-induced X chromosome inactivation can be skewed ([@B35]). For example, in *129/Castaneus* hybrid mice, the *129* allele is preferentially chosen for XCI. This stochastic allelic difference is associated with preferential expression of *Xist* from X^129^ rather than from X^CAS^ ([@B36]). The exact mechanism of nonrandom *Xist* expression is still unclear, but likely involves a myriad of coordinated events. We hypothesized that nonrandom *Xist* induction was associated with allelic differences in *Xist* RNA splicing.

To simultaneously measure spliced and unspliced *Xist* variants from *129* and *CAS* alleles, an exonic polymorphic site near the exon-intron boundary and compatible with splicing assay is needed. We cloned and sequenced all exon--intron boundaries using genomic DNA from *M. musculus domesticus 129SvJaeJ* and *M. musculus castaneus EiJ*. We found a new single nucleotide polymorphism (SNP) in exon 3 close to the 3′ splice site, which generates a Tfi1 enzyme recognition site specifically in the *CAS* allele (Figure [3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}).

![Allelic difference in *Xist* splicing is associated with non-random *Xist* induction. (**A**, **B**) Schematics of the primer locations and allele-specific restriction enzyme digestion for distinguishing the unspliced and spliced *Xist* transcripts from the *Xist^129^* and *Xist^CAS^* alleles. SNP induced Tfi1 cut site is present in exon 3 of the *Xist^CAS^* allele. (**C**) A representative gel showing Tfi1 specifically cuts exon 3 of *Xist^CAS/CAS^* genomic DNA but not *Xist^129/129^* DNA. Genomic DNA was amplified using the I1E2F or the E2F2 forward primer and the E2E3R primer before Tfi1 treatment. (**D**) Splicing assay detects allele-specific expression of unspliced and spliced transcripts from the *Xist^129^* and *Xist^CAS^* alleles before and after differentiation. (**E**) Quantification of intron 2 splicing ratios of *Xist^CAS^* and *Xist^129^* transcripts, respectively. (**F**) A representative RT-PCR virtual gel image shows the expression of unspliced *Xist^CAS^* and unspliced *Xist^129^* transcripts using I1E2-F and E2E3-R primers. (**G**) Ratios of unspliced *Xist^129^* transcript relative to unspliced *Xist^CAS^* transcript upon differentiation. Error bars indicate S.E.M. of three biological replicates. ns, *P*-value \> 0.05; \**P*-value \< 0.05; \*\**P*-value\< 0.01; \*\*\**P*-value \< 0.001.](gky1198fig3){#F3}

To test the new SNP, we PCR amplified the sequences around the SNP locus from *M. musculus domesticus 129SvJaeJ* and *M. musculus castaneus* EiJ genomic DNA. For both *Xist^129^* and *Xist^CAS^*, E2-F2 plus E2E3-R primers yielded a 281bp PCR product, and I1E2-F plus E2E3-R primers yielded a 408 bp product (Figure [3C](#F3){ref-type="fig"}). While the *129* amplicons were resistant to Tfi1 restriction enzyme digestion, the *CAS* amplicons were completely digested resulting in faster-migrating products (232 bp and 49 bp from the E2F2 amplicon, 359 bp and 49 bp from the I1E2-F amplicon). Therefore, Tfi1 digestion of RT-PCR products should be appropriate to distinguish *Xist^129^* and *Xist^CAS^* RNA.

To compare the splicing efficiency of *Xist^129^* and *Xist^CAS^* RNA, we performed RT-PCR followed by restriction fragment length polymorphism (RFLP) for allele-specific quantification based on the Tfi1 site. In undifferentiated F1 2-1 ES cells, we found neither *Xist^129^* nor *Xist^CAS^* were efficiently spliced (Figure [3D](#F3){ref-type="fig"}). Spliced *Xist^129^* and *Xist^CAS^* RNA were clearly up-regulated after differentiation. The majority of the spliced *Xist* transcript originated from *Xist^129^*. Even though both *Xist^129^* and *Xist^CAS^* RNA became more efficiently spliced, the *Xist^129^* splicing ratio (spliced/unspliced) was significantly larger than that of *Xist^CAS^*, suggesting higher splicing efficiency for *Xist*^129^ (Figure [3E](#F3){ref-type="fig"}). These data indicated efficient splicing of the *Xist^129^*allele is associated with preferential expression of *Xist^129^* RNA.

To further test the differential splicing efficiency of *Xist^129^* and *Xist^CAS^* RNA, we directly measured premature unspliced *Xist^129^* and *Xist^CAS^* RNA transcripts and calculated *Xist^129^/Xist^CAS^* before and after differentiation (Figure [3F](#F3){ref-type="fig"} and [G](#F3){ref-type="fig"}). I1E2-F and E2E3-R primers amplified only the unspliced *Xist* transcript. Even with presumed higher *Xist^129^*than *Xist^CAS^* transcription, unspliced *Xist^129^*precursor RNA was consistently lower than unspliced *Xist^CAS^* RNA, showing that *Xist^129^*is intrinsically spliced more effectively. Furthermore, the *Xist^129^/Xist^CAS^* ratio decreased as cells differentiated (Figure [3G](#F3){ref-type="fig"}). These data suggest that *Xist* RNA splicing might contribute to the choice mechanism selecting the future inactive X chromosome.

Allele specific *Xist* splicing is linked to the choice of inactive X chromosome {#SEC3-4}
--------------------------------------------------------------------------------

To test whether *Xist* RNA splicing is linked to the choice of inactive X chromosome, we compared allele-specific *Xist* splicing and allele-specific X-linked gene expression at the single cell level. We differentiated F1 2-1 cells and isolated single differentiating cells from embryoid bodies by FACS. We generated cDNA directly from single intact cells using SMART-seq. We then performed restriction fragment length polymorphism (RFLP) analysis to determine allele-specific *Xist* splicing and allele-specific expression of X-linked genes in single cells. Two X-linked genes (*G6pdx* and *Ogt*) were assessed to increase the rigor of the analysis and they were correlated when both were detected. For cells exhibiting dropouts (no detectable expression) for *G6pdx* or *Ogt1*, we relied on one detected gene.

We found some cells expressed *Xist* from both X chromosomes (Figure [4](#F4){ref-type="fig"}) and some did not ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Between the onset of *Xist* propagation and the full establishment of XCI is an intermediate state when *Xist* transcription continues from both chromosomes while (most) X-lined genes are being silenced from the inactive X chromosome ([@B37],[@B38]). When XCI is fully established, *Xist* is expressed only from the Xi chromosome and is turned off in the active chromosome ([@B4],[@B5],[@B9]). Therefore, those expressing *Xist* from both X chromosomes likely reflected the intermediate state, whereas those expressing *Xist* from a single X chromosome probably entered the irreversible state of XCI. We therefore named them intermediate cells and mature cells regarding XCI stages, respectively. In mature cells, allelic preference of *Xist* splicing could not be fairly assessed, and any data interpretation would be confounded by probable allelic bias of *Xist* transcription. In intermediate cells, allelic preference of *Xist* splicing can be more fairly examined with bi-allelic transcription.

![Allele specific *Xist* splicing is linked to the choice of inactive X chromosome. (**A**) Schematic diagram of the experimental procedure using embryoid body differentiation, FACS, and SMART-Seq for single cell analysis of allele-specific *Xist* splicing and allele-specific X-linked gene expression in F1 2-1 cells. (**B**) Restriction fragment length polymorphism analysis combined with splicing assay detects allelic specific expression of unspliced and spliced *Xist* transcripts from the X^129^ and X^CAS^ chromosomes in intermediate cells. (C and D) Restriction fragment length polymorphism analysis detects allelic expression of X-linked genes (**C**) *G6pdx* and (**D**) *Ogt* from the X^129^ and X^CAS^ chromosomes. Bulk means RNA samples from bulk cells.](gky1198fig4){#F4}

We found all the intermediate cells predominantly spliced *Xist^129^* RNA and simultaneously expressed the X-linked genes predominantly from the X^CAS^ chromosome (Figure [4](#F4){ref-type="fig"}). In 12 out of 13 cells (all except cell \#5), spliced *Xist^CAS^* was not detectable, demonstrating strong selection for allele-specific *Xist* splicing. Consequently, these cells expressed X-linked genes exclusively from the X^CAS^ chromosome. Cell \#5 had a weak signal for the spliced *Xist^CAS^* transcript and, interestingly, appeared to express *G6pdx* about equally from both X chromosomes. However, its *Ogt* expression from X^CAS^ was much stronger than from X^129^. Cell \#5 was likely at an earlier differentiation stage than the other intermediate cells, meaning it was on its way to splice *Xist^129^* exclusively and silence X^129^ chromosome completely.

Under the null hypothesis that *Xist* splicing is not linked to the choice of X-inactivation, the probability of observing 12 out of 13 individual intermediate cells that exclusively splice *Xist^129^* and inhibit X^129^ chromosome is close to 0 (or 0.0017 based on binomial distribution). In all mature cells, the spliced *Xist* and X-linked genes originated from different X chromosomes ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Therefore, we conclude that allele-specific *Xist* splicing is intrinsically linked to the choice of inactive X chromosome. This is also consistent with the notion that *Xist* splicing is required for *Xist*'s activity to induce XCI (see Disucssion).

*Xist* RNA splicing is impaired in *Ptbp1* mutant cells {#SEC3-5}
-------------------------------------------------------

To test whether PTBP1 influences *Xist* splicing, we generated female *Ptbp1^−/−^* ES cells from a *Ptbp1^loxp^* allele via homologous recombination. This *Ptbp1^loxp^* allele contains two loxp sites flanking *Ptbp1* exon 2, deletion of which eliminates functional PTBP1 proteins ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). The female *Ptbp1^−/−^* ES cell line was identified by genotyping PCR ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}) and confirmed by western blot using an antibody recognizing the N terminus of PTBP1 protein ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). When using an antibody reactive to the C-terminus of PTBP1, we detected a smaller and substantially less abundant protein ([Supplementary Figure S4D](#sup1){ref-type="supplementary-material"}), which might correspond to an N-terminally truncated PTBP1 protein isoform.

We next asked whether *Xist* splicing was affected in *Ptbp1^−/−^* cells. EB differentiation for 2 or 4 days in WT BL6 ES cells dramatically enhanced *Xist* splicing ([Supplementary Figure S4E-F](#sup1){ref-type="supplementary-material"}). *Ptbp1^−/−^* cells displayed lower splicing than WT cells. An alternative explanation for the shortage of spliced *Xist* transcripts in female *Ptbp1^−/−^* cells is decreased stability of the spliced transcript, such that any differentiation-enhanced splicing ratios would be attenuated by loss of the spliced transcript. However, we found no change in the stability of the spliced *Xist* transcript before or after differentiation ([Supplementary Figure S4G](#sup1){ref-type="supplementary-material"}). Nonetheless, PTBP1 depletion did not entirely block differentiation-induced *Xist* splicing at 2 or 4 days of differentiation.

We then asked whether enhanced *Xist* splicing correlated with any change in PTBP1 protein levels during EB differentiation but found no such correlation ([Supplementary Figure S4H](#sup1){ref-type="supplementary-material"}). PTBP1 was unchanged in the first day of differentiation and decreased in the second day of differentiation. *Xist* splicing is enhanced during the first day of differentiation while PTBP1 level has not changed. Second, differentiation reveals a negative relationship between PTBP1 level and *Xist* splicing: decrease in PTBP1 and increased in *Xist* splicing. *Xist* splicing efficiency is therefore not correlative with PTBP1 expression level but only requires a certain level of PTBP1 protein.

One possibility for the observed phenotype was that *Ptbp1^−/−^* ES cells differentiated more slowly than WT cells. To test this, we measured the expression of pluripotency marker *Nanog*, epiblast marker *Fgf5*, and neuroectoderm marker *Zfp521*. In WT cells, we found the expected decrease in Nanog expression upon differentiation ([Supplementary Figure S4I-K](#sup1){ref-type="supplementary-material"}). *Nanog* appeared to be slightly re-activated around day 4, as previously noted by Trott *et al.* ([@B39]). *Fgf5* was induced as early as day 2 of EB differentiation and *Zfp521* induced at day 4, consistent with sequential manifestation of development stages. We observed similar trends in *Ptbp1^−/−^* cell differentiation except that PTBP1 knockout appeared to accelerate the differentiation ([Supplementary Figure S4I--K](#sup1){ref-type="supplementary-material"}). If PTBP1 controlled *Xist* splicing through its influence on differentiation, *Ptbp1^−/−^* cells should have showed stronger induction of *Xist* splicing, which is not the case. Therefore, impaired *Xist* splicing in *Ptbp1^−/−^* cells cannot be explained by slow differentiation. We conclude PTBP1 affects *Xist* splicing independent of PTBP1's interactions with cellular differentiation ([Supplementary Figure S4L](#sup1){ref-type="supplementary-material"}).

DISCUSSION {#SEC4}
==========

Our studies provide comprehensive evidence for splicing as an essential regulatory step in *Xist* induction. First, naïve stem cells expressed mostly unspliced *Xist*. Second, after normalizing to total *Xist* RNA levels, spliced *Xist* was upregulated and unspliced *Xist* was reduced during the early stage of differentiation. Third, differentiation-induced *Xist* splicing was significantly impaired (though not completely arrested) in *Ptbp1* mutant cells, suggesting involvement of *trans*-factors in its splicing regulation. Fourth, in hybrid *Xist^129^/Xist^CAS^* cells, *Xist^129^* and *Xist^CAS^* RNA were differentially spliced, indicating the existence of splicing *cis*-elements responsive to differentiation. Since the intrinsic bias for expressing *Xist* from the 129 allele has been ascribed to effects of the X-controlling element (Xce) ([@B35]), future studies should focus on Xce to identify splicing-controlling elements. Finally, allele-specific *Xist* splicing is intrinsically linked to the choice of inactive X chromosome.

*Xist* splicing probably has been overlooked historically because: (i) *Xist* was first cloned as spliced cDNA from somatic cells; (ii) the spliced *Xist* cDNA transgene is sufficient for XCI; (iii) methods for *Xist* detection have been designed to detect the spliced *Xist* transcript and (iv) *Xist* splicing was thought to occur quickly and passively.

To precisely measure splicing, the amplicon sizes for the spliced and unspliced transcripts should be comparable. PCR efficiency is skewed toward smaller amplicons (or spliced transcripts). The larger the difference between the amplicons, the greater the bias. Our splicing assay examining intron 2 yielded amplicon sizes of 239 and 90 bp (Figure [1D](#F1){ref-type="fig"}). For analyzing the largest *Xist* intron (i.e. intron 1), multiplex PCR was used to produce amplicons of similar sizes (127 bp versus 74 bp, Figure [1E](#F1){ref-type="fig"}). We also used a primer pair targeting exon 2 and 6, which yielded a unspliced product (1930 bp) and a spliced product (562 bp, Figure [1F](#F1){ref-type="fig"}). In this case, the unspliced *Xist* has become difficult to detect even in ES cells. When we assayed the splicing of intron 1, intron 2 and introns 2--5 with the same RNA samples, the spliced/unspliced ratios increased in that order, which correlates with the difference in amplicon sizes.

Another required consideration for detecting unspliced *Xist* transcripts is the pluripotency state of ES cells. An intrinsic relationship between pluripotency and X chromosome inactivation has been reported and the underlying mechanism through regulating *Xist* expression has been suggested ([@B40]). *Xist* splicing may be negatively influenced by the pluripotency state, and spontaneous ES cell differentiation would hinder revealing the true splicing status of *Xist* in ES cells.

Although *Xist* splicing has been below the radar, its functional importance is hinted at in previous publications. The most convincing sufficiency test for *Xist*'s direct role in chromosome inactivation was based on doxycycline-inducible *Xist* transgene lines ([@B10]). These lines were transduced with a 15kb mouse *spliced Xist* cDNA. Upregulation of this ectopic spliced *Xist* by doxycycline was sufficient to trigger inactivation of the chromosome containing the transgene in the undifferentiated ES cells. The result suggests that all factors except spliced *Xist* required for XCI initiation are present in ES cells. Just as our research shows that naïve ES cells express unspliced *Xist*, Wutz and Jaenisch\'s results imply that spliced *Xist* rather than unspliced *Xist* is essential to initiate XCI.

Two additional studies, though not specifically investigating *Xist* splicing, also show a strong relationship between the *Xist* splicing status and *Xist*'s ability to inactivate chromosomes. The mutant cells in these two studies exhibited a gain and a loss of *Xist* splicing. Heard *et al.* introduced a 480-kb YAC containing full human *Xist* gene (exons + introns) into mouse ES cells ([@B41],[@B42]). Interestingly, even before *in vitro* differentiation the undifferentiated mouse ES cells tended to express the spliced *Xist* RNA from the human transgene, which functionally coated the host chromosomes. This unexpected result was not explored further in their publications but, similar to results from Wutz *et al.*, implied the functional importance of *Xist* splicing.

In the second study, Royce-Tolland *et al.* deleted the A repeat of the *Xist* gene on the allele 129 of 129/CAS hybrid cells ([@B43]). The A repeat sequence resides within exon 1 and is necessary for XCI ([@B44]). These differentiated mutant cells did not inactivate the X^129^ chromosome. Interestingly, the mutant cells also failed to splice *Xist* RNA from allele 129. These results are consistent with the notion that *Xist* splicing correlates with functional XCI.

Our single cell analyses further strengthen the notion that *Xist* splicing is intrinsically linked to the choice of inactive chromosome. The striking association between allele specific *Xist* splicing and allele specific X-linked gene expression at the single cell level show that *Xist* splicing would be a critical regulatory step. Some studies suggested that differential transcription induction might not be the selection mechanism for allele-specific *Xist* expression. For example, Panning\'s group reported that the choice of *Xist* allele for induction was not initiated by unequal distribution of histone modification marks (e.g. H3K27me3 and H3K4me2) ([@B43]). Demethylation of the *Xist* locus due to deficient DNA methyltransferase activity activated *Xist* expression in somatic but not undifferentiated ES cells, suggesting DNA methylation is inessential for *Xist* repression in ES cells ([@B45]). These data raise the possibility of a role for post-transcriptional regulation in *Xist* allele induction.

We have not isolated cells that splice *Xist^CAS^*. In bulk-cell analysis of allele-specific expression, the ratio of spliced *Xist^129^* to spliced *Xist^CAS^* is about 10:1. Therefore, the chance of isolating cells expressing spliced *Xist^CAS^* is low to begin with. The ratio of spliced *Xist^129^* cells to spliced *Xist^CAS^* cells may be further skewed by FACS. We used three stringent gating steps to select single cells (Methods and Materials). Only ∼1% of total FACS events (cells) passed these stringent criteria. It is possible that some idiosyncratic paraments disproportionally led to the discard of the spliced *Xist^CAS^* cells. We also note that allelic expression levels vary among cells partly due to heterogeneity in differentiation stages (or cell states) and intrinsic technical variance and bias in this kind of single cell analysis ([@B46],[@B47]).

*Xist* splicing might be essential for *Xist* to form high-order structures to spread throughout and coat X chromosome, which is an activity observed only for the spliced *Xist* in literature. *Xist* introns could serve as a structural hindrance by themselves or as binding sites for factors blocking *Xist*'s ability to tether to, spread, or coat X chromosome. Alternatively, exon-exon junctions could create new binding sites for factors that act positively in mediating XCI.

Our data provides an explanation to reconcile some previous observations. While some believed transcription upregulation was the mechanism of inducing *Xist*, others disagreed with transcriptional activation when using an intron 1 probe to measure *Xist* transcription ([@B37]). We observed a significant increase in total *Xist*, and an even larger increase in spliced *Xist*, but a modest decrease in unspliced *Xist*. We propose that differentiation up-regulates *Xist* transcription and splicing. Increased splicing efficiency occludes up-regulation of the unspliced *Xist* transcripts (measured by the intron 1 probe). Therefore, our data is consistent with previous publications and, at the same time, provides novel insights.

Repression of *Xist* splicing presumably provides a fail-safe mechanism to inhibit *Xist* activity in ES cells. The repression of *Xist* in ES cells has been attributed to pluripotency factors, because de-repression of pluripotency factors up-regulate *Xist* expression in female cells ([@B40],[@B48]). We found *Xist* transcription is detectable in ES cells, but its splicing is repressed, meaning *Xist* splicing is not the default. Splicing may be a context-dependent regulatory checkpoint for *Xist* expression, thereby contributing to regulation of *Xist* function. Determining the source of *Xist* splicing repression and activation could reveal novel splicing regulatory mechanisms.

PTBP1 significantly impairs but does not completely block differentiation-induced *Xist* splicing. The influence of differentiation and that of PTBP1 on *Xist* splicing are likely uncoupled, even though PTBP1 and differentiation are intrinsically linked ([Supplementary Figure S4L](#sup1){ref-type="supplementary-material"}). PTBP1's effect on *Xist* splicing is not because PTBP1 restrains differentiation. Likewise, differentiation-induced *Xist* splicing is not due to differentiation-mediated downregulation of PTBP1. These suggest that PTBP1 plays a permissive rather than instructive role in regulating *Xist* splicing and PTBP1's effect may be indirect. PTBP1 does interact with E repeat of *Xist* RNA transcripts, but it is unclear how this interaction could mediate splicing of all *Xist* introns ([@B21]). One possibility is that the E repeat serves as a 'landing pad' for PTBP1 to bring other splicing factors in proximity. Alternatively, PTBP1 might control the expression of splicing factors critical for *Xist* RNA splicing.
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